Unicycive Therapeutics, Inc. UNCY
focused on identifying, developing, and commercializing innovative therapies to address significant unmet medical needs, with an initial
focus on kidney disease. Founded in 2016, Unicycive was established to create a streamlined and efficient drug development platform capable
of accelerating the advancement of promising therapies from discovery to commercialization. Currently, our two programs are focused on
kidney disease, an area we believe we have the potential to offer medical benefit. Our initial focus is on developing drugs and getting
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | $675.0K | $951.0K | — | — | — |
| R&D | $9.1M | $20.0M | $12.9M | $12.4M | $6.1M | $1.0M | — |
| SG&A | $20.4M | $12.1M | $8.5M | $6.6M | $245.0K | $58.0K | — |
| Total operating expenses | $29.5M | $32.1M | $21.4M | $19.0M | $9.0M | $2.0M | — |
| Operating income | -$29.5M | -$32.1M | -$20.8M | -$18.1M | -$9.0M | -$2.0M | — |
| Interest expense | $71.0K | $71.0K | $82.0K | $6.0K | $628.0K | $244.0K | — |
| Net income | -$26.6M | -$36.7M | -$30.5M | -$18.1M | -$10.0M | -$2.3M | — |
| EPS, basic | -1.67 | -5.65 | -1.28 | -1.20 | -0.86 | -0.27 | — |
| EPS, diluted | -1.67 | -5.65 | -1.28 | -1.20 | -0.86 | — | — |
| Shares, diluted (wtd. avg.) | 15.9M | 6.7M | 24.5M | 15.1M | 11.7M | 8.5M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $29.2M | $26.1M | $9.7M | $455.0K | $16.6M | — | $15.0K |
| Short-term investments | $12.1M | — | — | — | — | — | — |
| Inventory | — | — | — | $2.2M | $1.8M | — | — |
| Total current assets | $49.0M | $30.9M | $13.4M | $2.6M | $18.4M | $204.0K | — |
| Property, plant and equipment | $66.0K | $75.0K | $26.0K | $22.0K | $28.0K | — | — |
| Total assets | $49.1M | $31.7M | $14.2M | $2.8M | $18.7M | $204.0K | — |
| Accounts payable | $383.0K | $1.1M | $839.0K | $892.0K | $742.0K | $184.0K | — |
| Total current liabilities | $18.9M | $24.1M | $17.5M | $3.3M | $2.1M | $2.9M | — |
| Total liabilities | $18.9M | $24.2M | $18.0M | $3.3M | $2.3M | $2.9M | — |
| Retained earnings | -$127.8M | -$101.3M | -$64.5M | -$34.0M | -$15.9M | -$5.9M | — |
| Total equity | $30.2M | $7.4M | -$3.8M | -$466.0K | $16.5M | -$2.7M | -$884.0K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$31.3M | -$28.6M | -$18.3M | -$15.7M | -$5.8M | -$1.5M | — |
| Depreciation and amortisation | $34.0K | $22.0K | $9.0K | $7.0K | $468.0K | $63.0K | — |
| Stock-based compensation | $2.6M | $2.4M | $1.8M | $1.0M | $966.0K | — | — |
| Capital expenditure | $24.0K | $72.0K | $12.0K | $2.0K | $29.0K | — | — |
| Investing cash flow | -$12.1M | -$72.0K | -$12.0K | -$2.0K | -$29.0K | — | — |
| Financing cash flow | $46.5M | $45.1M | $27.5M | -$471.0K | $22.4M | $1.4M | — |
| Dividends paid | — | $1.1M | $900.0K | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-035903.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $951.0K | $675.0K | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$2.3M | -$10.0M | -$18.1M | -$30.5M | -$36.7M | -$26.6M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Other event Item 8.01
- Results announced Item 2.02
- Results announced Item 2.02
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |